AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
Go back to AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)| AngioDynamics, Inc. (NASDAQ: ANGO) | Delayed: 12.39 +0.24 (1.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.15 | 52 Week High | $17.64 | |||
| Open | $12.18 | 52 Week Low | $9.71 | |||
| Day High | $12.58 | P/E | N/A | |||
| Day Low | $12.11 | EPS | $-0.07 | |||
| Volume | 300,731 | |||||
